NFKB1 and Eczematoid dermatitis: While other pathways (e.g., JNK and STAT3) contribute to eczema, p38/NF-κB and JAK1-STAT6 were prioritized due to their clinical relevance—both are validated therapeutic targets in refractory eczema, making them ideal for evaluating MTMZM's translational potential.